HR and breast cancer: The 21-gene RS is the most widely used multigene assay in early BC with predictive and prognostic value in HR+/HER2-, node-negative patients (19, 22), and it showed independently prognostic value for survival in ER+/HER2- de novo stage IV BC patients in a previous prospective study (11).